CARsgen says first patient dosed in China Phase I registrational trial of CT1190B CAR-T for R/R LBCL

PUBT · 2d ago
CARsgen says first patient dosed in China Phase I registrational trial of CT1190B CAR-T for R/R LBCL
  • CARsgen dosed the first patient in China in a registrational Phase I trial of CT1190B for relapsed or refractory large B-cell lymphoma.
  • The study targets patients who failed at least two prior standard treatment lines, marking a step toward a potential China filing.
  • Early investigator-initiated trial results were already presented as a poster at the 2026 European Hematology Association congress.
  • No new efficacy or safety outcome was disclosed in the announcement beyond confirmation of trial initiation and patient dosing.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CARsgen Therapeutics Holdings Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260929-12349838), on September 29, 2026, and is solely responsible for the information contained therein.